Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Affiliations

• ¹ Sarah Cannon Research Institute and the Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA. dyardley@tnonc.com.
• ² University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
• ³ Weston Park Hospital, Sheffield Cancer Research Center, Sheffield, England.
• ⁴ Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, and Istituto Oncologico Veneto IRCCS, Padova, Italy.
• ⁵ Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
• ⁶ Celgene Corporation, Summit, NJ, USA.
• ⁷ Centre de Lutte Contre le Cancer d'Auvergne, Clermont Ferrand, France.
• ⁸ Texas Oncology-Baylor Charles A. Sammons Center; US Oncology, Dallas, TX, USA.
• ⁹ Breast Center, University of Munich, Munich, Germany.